Browse > Article
http://dx.doi.org/10.4070/kcj.2018.0231

Left Atrial Appendages Occlusion: Current Status and Prospective  

Sharma, Sharan Prakash (Kansas City Heart Rhythm Institute)
Park, Peter (Kansas City Heart Rhythm Institute)
Lakkireddy, Dhanunjaya (Kansas City Heart Rhythm Institute)
Publication Information
Korean Circulation Journal / v.48, no.8, 2018 , pp. 692-704 More about this Journal
Abstract
Stroke continues to be a major cause of morbidity and mortality in atrial fibrillation (AF) patients. Oral anticoagulation (OAC) provides protection against stroke and peripheral embolization in AF but significant proportion of patients could not be started on anticoagulation because of bleeding complications. Left atrial appendage harbors clot in about 90% of nonvalvular AF. The advent of left atrial appendage occlusion (LAAO) techniques has provided these patients with alternative to OAC for stroke prophylaxis. Multiple LAAO devices are currently available with Watchman and Amulet being the most commonly used in clinical practice. Randomized studies are available for Watchman device only. Data on Amplatzer Cardiac Plug, Amulet and Lariat devices are limited by the paucity of randomized data. Long-term data on different LAAO techniques are showing promising results. Device related thrombosis continues to be a serious complication associated with LAAO. Future studies should look into comparative effectiveness between different LAAO techniques, optimal patient selection, risk of complications, and anticoagulant treatment after LAAO. This article aims to provide current available evidence on efficacy and safety of different LAAO devices and future prospective.
Keywords
Left atrial appendage occlusion; Atrial fibrillation; Watchman; Amulet; Lariat;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Genovesi S, Slaviero G, Porcu L, et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: peri-procedural outcomes from an Italian dialysis population. Int J Cardiol 2018;262:38-42.   DOI
2 Lee OH, Kim JS, Pak HN, et al. Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol 2018;121:1534-9.   DOI
3 Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 2016;13:1030-6.   DOI
4 Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108-18.   DOI
5 Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565-72.   DOI
6 Ailawadi G, Gerdisch MW, Harvey RL, et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg 2011;142:1002-9, 1009.e1.   DOI
7 Regueiro A, Bernier M, O'Hara G, et al. Left atrial appendage closure: initial experience with the ultraseal device. Catheter Cardiovasc Interv 2017;90:817-23.   DOI
8 Coherex WAVECREST I left atrial appendage occlusion study [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2015 [cited 2018 May 15]. Available form: https://clinicaltrials.gov/ct2/show/NCT02239887?cond=WAVECREST&rank=1.
9 Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2017;69:253-61.
10 Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24.   DOI
11 Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015;65:2614-23.   DOI
12 Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465-74.   DOI
13 Betts TR, Leo M, Panikker S, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: a multicenter registry. Catheter Cardiovasc Interv 2017;89:484-92.   DOI
14 Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg 2015;47:847-54.   DOI
15 Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 2018;71:1528-36.   DOI
16 Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007;49:1490-5.   DOI
17 Main ML, Fan D, Reddy VY, et al. Assessment of device-related thrombus and associated clinical outcomes with the Watchman left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF trial). Am J Cardiol 2016;117:1127-34.   DOI
18 Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol 2013;61:2551-6.   DOI
19 Meincke F, Schmidt-Salzmann M, Kreidel F, Kuck KH, Bergmann MW. New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN(R) device in patients not taking warfarin. EuroIntervention 2013;9:463-8.   DOI
20 Bosche LI, Afshari F, Schone D, Ewers A, Mugge A, Gotzmann M. Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device. Clin Cardiol 2015;38:720-4.   DOI
21 Enomoto Y, Gadiyaram VK, Gianni C, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm 2017;14:19-24.   DOI
22 Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013;61:1790-8.   DOI
23 Reddy VY, Akehurst RL, Armstrong SO, et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 2016;18:979-86.   DOI
24 Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR Jr. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol 2015;66:2728-39.   DOI
25 Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1170-9.   DOI
26 Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1188-94.   DOI
27 Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 2017;13:867-76.   DOI
28 Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62:96-102.   DOI
29 Lopez-Minguez JR, Nogales-Asensio JM, Infante De Oliveira E, et al. Long-term event reduction after left atrial appendage closure. Results of the Iberian Registry II. Rev Esp Cardiol (Engl Ed) 2018:S1885-5857(18)30112-9.
30 Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 2013;82:283-9.   DOI
31 Regueiro A, Cruz-Gonzalez I, Bethencourt A, et al. Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation. J Interv Card Electrophysiol 2018;52:53-9.   DOI
32 Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015;12:1501-7.   DOI
33 January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104.   DOI
34 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-78.   DOI
35 Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion. Catheter Cardiovasc Interv 2016;87:E39-43.   DOI
36 Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017;70:2964-75.   DOI
37 Berti S, Pastormerlo LE, Rezzaghi M, et al. Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 2016;102:1969-73.   DOI
38 Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.   DOI
39 Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.   DOI
40 Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31:55-62.   DOI
41 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.   DOI
42 Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.   DOI
43 Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9.   DOI
44 Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.   DOI
45 Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 2007;38:624-30.   DOI
46 Majunke N, Sandri M, Adams V, et al. Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage with the Watchman device. J Invasive Cardiol 2015.27:448-52.
47 Lakkireddy D, Turagam M, Afzal MR, et al. Left atrial appendage closure and systemic homeostasis: the LAA HOMEOSTASIS study. J Am Coll Cardiol 2018;71:135-44.   DOI
48 Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. Heart Rhythm 2015;12:52-9.   DOI
49 Badhwar N, Lakkireddy D, Kawamura M, et al. Sequential percutaneous LAA ligation and pulmonary vein isolation in patients with persistent AF: initial results of a feasibility study. J Cardiovasc Electrophysiol 2015;26:608-14.   DOI
50 Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage. Interact Cardiovasc Thorac Surg 2012;15:416-8.   DOI
51 aMAZE Study: LAA ligation adjunctive to PVI for persistent or longstanding persistent atrial fibrillation (aMAZE) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02513797.
52 AMPLATZERTM AmuletTM LAA Occluder trial (Amulet IDE) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02879448?cond=Amplatzer&draw=2&rank=1.
53 Left atrial appendage closure vs. novel anticoagulation agents in atrial fibrillation (PRAGUE-17) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2016 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02426944?cond=PRAGUE+17&rank=1.
54 U.S. Food and Drug Administration. Watchman LAA closure technology -P130013 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2018 May 17]. Available form: https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130013a.pdf.
55 Holmes DR, Reddy VY, Turi ZG, et al.PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42.   DOI
56 Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12.   DOI
57 Koskinas KC, Shakir S, Fankhauser M, et al. Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices. JACC Cardiovasc Interv 2016;9:1374-83.   DOI
58 Kleinecke C, Park JW, Godde M, Zintl K, Schnupp S, Brachmann J. Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J 2017;24:131-8.   DOI
59 Lopez Minguez JR, Asensio JM, Gragera JE, et al. Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart 2015;101:877-83.   DOI
60 Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol 2015;104:656-65.   DOI
61 Abualsaud A, Freixa X, Tzikas A, et al. Side-by-side comparison of LAA occlusion performance with the Amplatzer cardiac plug and Amplatzer Amulet. J Invasive Cardiol 2016.28:34-8.
62 Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [cited 2018 May 17]. Available form: https://clinicaltrials.gov/ct2/show/NCT02928497?cond=ASAP+TOO&rank=1.